Skip to main content

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors.

The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, making him an invaluable asset to the Company. His appointment will help accelerate the Company's mission of improving patients' lives in the prevention, treatment and management of cardiovascular disease, by driving key opportunities for research, collaborations, and partnerships.

“I am thrilled to welcome Dr. Ramjee to our team. His exceptional expertise in cardiovascular medicine will be pivotal in advancing our innovation and research efforts. His guidance will be crucial in forging new collaborations and enhancing our impact on cardiac care globally,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.

Dr. Vimal Ramjee: A Cardiovascular Expert

Dr. Vimal Ramjee's career in cardiovascular medicine is marked by significant academic and professional achievements. He is a cardiologist and health innovation leader working at the intersection of medicine, digital health technologies, and artificial intelligence algorithms. He has dedicated his career to improving health outcomes for people with cardiovascular disease. He earned his Bachelor of Science degree from Emory University, followed by his medical degree from the Mount Sinai School of Medicine in New York. After medical school, Dr. Ramjee completed his residency in internal medicine at Emory Hospital in Atlanta. He then pursued a fellowship in cardiovascular disease and advanced cardiovascular imaging and translational research at the Hospital of the University of Pennsylvania in Philadelphia.

Dr. Ramjee holds 7 active board certifications, in Cardiology, AI in Medicine, Internal Medicine, Echocardiography, Cardiovascular CT, Nuclear Medicine, & Culinary Medicine. His contributions to the scientific field have been recognized with prestigious accolades from the American College of Cardiology (ACC), NIH, Northwestern University, and American College of Physicians (ACP). His work has been published in high-impact peer-reviewed journals, including JACC, JASE, The Journal of Clinical Investigation, Resuscitation, Echocardiography, Journal of Vascular Surgery, Annals of the New York Academy of Science, among others.

“I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee. “Cardio Diagnostics is at the forefront of developing innovative diagnostic tools that have the potential to make a real difference in the lives of patients. I am confident that my experience and expertise will be valuable as the company continues to grow and drive new innovations in cardiac care.”

As a Strategic Advisor, Dr. Ramjee will partner with Cardio Diagnostics’ management team on several initiatives, including new research studies and capitalizing on emerging opportunities. Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care. His role will be instrumental in ensuring that the Company continues to be at the forefront of precision cardiovascular medicine.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Forms 10-Q for the periods ended March 31, 2023 and September 30, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.